Cardarine (GW-501516): What the Research Shows

Research Use Only: This article summarises published scientific literature for laboratory and research audiences. It is not medical advice, and Cardarine is not approved for human or veterinary use.

What is Cardarine?

Cardarine (GW-501516) is a compound studied in the research literature as a PPAR-delta (PPARδ) agonist. It was originally investigated in a pharmaceutical research programme focused on metabolic and lipid pathways and is now a common subject in laboratory receptor studies.

Where Cardarine sits in the research literature

The evidence base is preclinical, focused on PPAR-delta signalling and metabolic gene-expression models in cells and animals. Importantly, development was discontinued after long-term animal studies raised safety concerns, which is essential context for anyone handling the compound.

Reported areas of preclinical interest

• PPAR-delta agonism: studied for effects on lipid-metabolism and endurance-related gene pathways in laboratory models.
• Metabolic signalling: examined in cell and animal metabolic research.

Safety and regulatory status

Cardarine is not an approved medicinal product. Long-term rodent studies associated the compound with tumour development, and it appears on the World Anti-Doping Agency prohibited list. These points make its research-only status especially important.

Why the “research use only” label matters

Cardarine is supplied strictly for laboratory and scientific research and is not for human or veterinary consumption.

Frequently asked questions

What does Cardarine do in research?

It is studied as a PPAR-delta agonist affecting lipid and metabolic gene pathways in laboratory models.

Is Cardarine approved or safe for human use?

No. It is not approved, its development was discontinued after animal safety concerns, and it is banned in sport. It is a research material only.

Key takeaways

Cardarine (GW-501516) is a PPAR-delta agonist studied in metabolic research, with important safety and regulatory caveats. It is a research material only. Review the Cardarine research product.

References

References sourced via PubMed.

1. Serrano-Marco L, Barroso E, El Kochairi I, et al. The PPARβ/δ agonist GW501516 inhibits IL-6-induced STAT3 activation and insulin resistance in human liver cells. Diabetologia. 2012;55(3):743-751. DOI · PubMed 22179221.
2. Qiu YY, Zhang J, Zeng FY, Zhu YZ. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of NAFLD. Pharmacol Res. 2023;192:106786. DOI · PubMed 37146924.

Disclaimer: This article is for informational and educational purposes for a research audience. It is not medical advice. Products referenced are sold strictly for laboratory research and are not for human or veterinary use.